[424B5] BioLineRX Ltd Prospectus Supplement (Debt Securities)

Rhea-AI Filing Summary

Nikul Patel, a director of Champion Homes, Inc. (NYSE: SKY), filed a Form 4 disclosing the grant of 2,259 restricted stock units (RSUs) on 07/24/2025 under the company’s 2018 Equity Incentive Plan. Each RSU converts into one share of common stock and will vest in full on the earlier of the first anniversary of the vesting commencement date or the 2026 Annual Meeting, assuming continued board service.
The award, recorded at an indicative reference price of $66.39 per share, increases Patel’s direct beneficial ownership to 6,679 shares. No derivative instruments were involved, and no cash changed hands.
This appears to be a routine director equity grant designed to align compensation with shareholder interests; it carries no immediate strategic, operational, or financial implications for Champion Homes.

Insights

Insider Trading Analyst

TL;DR: Routine RSU grant; minor ownership increase; neutral market impact.

The 2,259-share RSU award—worth roughly $150k—reflects standard board compensation. Patel’s holdings rise to 6,679 shares, well under 0.1% of outstanding stock, and vest within a year subject to service. There were no open-market trades or derivative exercises. Given SKY’s multi-billion-dollar market cap, the filing is informational with negligible signalling value. Investors should view it as housekeeping rather than a catalyst.

Filed pursuant to Rule 424(b)(5)

Registration No. 333-276323

PROSPECTUS SUPPLEMENT

(To prospectus dated January 5, 2024)

BioLineRx Ltd.

Up to $4,870,000 of
American Depositary Shares Representing Ordinary Shares

We are filing this prospectus supplement to amend the prospectus, dated January 5, 2024, filed as a part of our registration statement on Form F-3 (File No. 333-276323), or the Registration Statement, as supplemented by our prospectus supplement, dated April 11, 2025, or the Prior Prospectus, to update the maximum amount of securities we are eligible to sell under our Registration Statement pursuant to General Instruction I.B.5 of Form F-3. This prospectus supplement amends and supplements the information in the Prior Prospectus relating to the offering, issuance and sale by us of our American Depositary Shares, or ADSs, representing our ordinary shares, par value NIS 0.10 per share, from time to time that may be issued and sold under the at-the-market offering agreement, dated September 3, 2021, or the Offering Agreement, by and between us and H.C. Wainwright & Co., LLC, or Wainwright, as sales agent. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto.

As a result of these limitations and the current public float of our ordinary shares, including ordinary shares represented by ADSs, and in accordance with the terms of the Sales Agreement, we may offer and sell ADSs having an aggregate offering price of up to $4,870,000 from time to time through Wainwright, which does not include the ADSs having an aggregate sales price of approximately $3.2 million that were sold pursuant to the Prior Prospectus to date.

Our ADSs are listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “BLRX”. On July 24, 2025, the closing price of our ADSs on the Nasdaq was $4.51 per ADS. Our ordinary shares also trade on the Tel Aviv Stock Exchange, or TASE, under the symbol “BLRX”. On July 24, 2025, the last reported sale price of our ordinary shares on the TASE was NIS 0.025 or $0.0075 per share (based on the exchange rate reported by the Bank of Israel on the same day).

The aggregate market value of our outstanding voting and non-voting common equity held by non-affiliates as of the date of this prospectus supplement, based on the closing price of the ADSs on the Nasdaq on June 9, 2025, as calculated in accordance with General Instruction I.B.5. of Form F-3, was approximately $24.2 million. Pursuant to General Instruction I.B.5 of Form F-3, in no event will we sell securities in a primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75,000,000. During the prior 12 calendar month period that ends on, and includes, the date of this prospectus supplement (excluding this offering), we sold securities with an aggregate market value of $3,194,586 pursuant to General Instruction I.B.5 of Form F-3. In the event that we may sell additional amounts under the Sales Agreement, we will file another prospectus supplement prior to making such additional sales.

Investing in our securities involves a high degree of risk. You should read this prospectus supplement and the accompanying prospectus as well as the information incorporated herein and therein by reference carefully before you make your investment decision. See “Risk Factors” beginning on page S-5 of the ATM Prospectus and on page S-1 of the accompanying prospectus, and the risk factors described in other documents incorporated by reference therein, to read about the factors you should consider before investing in our securities.

Neither the U.S. Securities and Exchange Commission, the Israel Securities Authority nor any state or other foreign securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. 

H.C. Wainwright & Co.

The date of this prospectus supplement is July 25, 2025

FAQ

What insider transaction did Nikul Patel report for Champion Homes (SKY)?

2,259 restricted stock units were granted on 07/24/2025 under the 2018 Equity Incentive Plan.

When will the 2,259 RSUs granted to Nikul Patel vest?

They vest in full on the earlier of the first anniversary of the vesting commencement date or the 2026 annual shareholder meeting.

How many Champion Homes shares does Nikul Patel now beneficially own?

After the grant he directly owns 6,679 shares.

Was the transaction an open-market purchase or sale?

No. It was a restricted stock unit award; no open-market transaction occurred.

What is the indicative value of the RSU grant reported in the Form 4?

At the reported price of $66.39, the grant is worth roughly $150,000.

Does this Form 4 filing impact Champion Homes’ financial guidance?

No. The filing is routine compensation disclosure and has no stated effect on earnings or guidance.